Skip to main content

Table 2 Clinical and immunological characteristics of SLE-related APS patients and SLE-"aPL carriers"

From: Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings

 

SLE-APS

SLE-"aPL carriers"

Total patients

6

7

Female–male sex

6–0

7–0

Age (years, mean ± SD)

53 ± 12

46 ± 12

Disease duration (years, mean ± SD)

18 ± 15

15 ± 11

Remission (SLEDAI < 2)

6

7

Active disease (SLEDAI > 2)

0

0

Clinical domains

Cutaneous domain

5

7

Arthritis domain

1

2

Neurological domain

1

0

Serositis domain

1

1

Hematologic domain

1

3

Renal domain

0

1

Current therapy

Glucocorticoids (prednisone ≤ 5 mg per day)

5

7

Hydroxychloroquine

2

5

cDMARDs (methotrexate, azathioprine, mycophenolate mofetil)

4

4

  1. SLE systemic lupus erythematosus, SLEDAI systemic lupus erythematosus disease activity index, APS antiphospholipid syndrome, aPL antiphospholipid antibodies, SD standard deviation, cDMARDs conventional disease-modifying anti-rheumatic drugs